belantamab mafodotin
gsk
oab presenter rakesh popat reviewed the need for risk assessment for the occurrence of ocular conditions (e.g., dry eye, keratopathy) when using the therapeutic belantamab mafodotin for pts with rrmm. #ims2022 
To cure myeloma by fostering research, education and excellence in clinical care worldwide.